Vandetanib
From Wikipedia, the free encyclopedia
|
Vandetanib
|
|
| Systematic (IUPAC) name | |
| N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7- [(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C22H24BrFN4O2 |
| Mol. mass | 475.354 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 5 days (mean) |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. It is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).
Vandetanib is being developed by AstraZeneca.
[edit] External links
- Cancerline.com: Vandetanib Information for Physicians
- AZ-Trials.com: AstraZeneca Clinical Trials Patient Recruiting (US)

